KPTI (Karyopharm Therapeutics) Total Assets: $131.4 Mil (As of Mar. 2026)


KPTI Karyopharm Therapeutics Inc KPTI
52 GF Score
Price $9.60
GF Value $6.34
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Karyopharm Therapeutics Total Assets?

Karyopharm Therapeutics KPTI +0.63% 52 Total Assets is $131.4 Mil as of Mar. 2026. GuruFocus rates KPTI with a GF Score™ of 52/100 and a GF Value™ of $6.34 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Karyopharm Therapeutics's Total Assets for the quarter that ended in Mar. 2026 was $131.4 Mil.

During the past 12 months, Karyopharm Therapeutics's average Total Assets Growth Rate was -29.80% per year. During the past 3 years, the average Total Assets Growth Rate was -17.70% per year. During the past 5 years, the average Total Assets Growth Rate was -8.80% per year. During the past 10 years, the average Total Assets Growth Rate was 6.10% per year.

During the past 13 years, Karyopharm Therapeutics's highest 3-Year average Total Assets Growth Rate was 251.10%. The lowest was -31.10%. And the median was 27.95%.

Total Assets is connected with ROA %. Karyopharm Therapeutics's annualized ROA % for the quarter that ended in Mar. 2026 was -74.69%. Total Assets is also linked to Revenue through Asset Turnover. Karyopharm Therapeutics's Asset Turnover for the quarter that ended in Mar. 2026 was 0.29.

Karyopharm Therapeutics  (NAS:KPTI) Total Assets Explanation

Total Assets is connected with ROA %.

Karyopharm Therapeutics's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-89.568/( (108.416+131.417)/ 2 )
=-89.568/119.9165
=-74.69 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Karyopharm Therapeutics's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=35.066/( (108.416+131.417)/ 2 )
=35.066/119.9165
=0.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Karyopharm Therapeutics Total Assets Related Terms

Karyopharm Therapeutics Total Assets Historical Data

* Premium members only.

The historical data trend for Karyopharm Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Karyopharm Therapeutics Total Assets Chart

Karyopharm Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 305.31 358.17 240.44 164.42 108.42

Karyopharm Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 127.71 104.88 96.23 108.42 131.42
KPTI
52GF Score
Karyopharm Therapeutics Inc KPTI
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Karyopharm Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Karyopharm Therapeutics's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=-292.926+401.342
=108.4

Karyopharm Therapeutics's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=-265.646+397.063
=131.4

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $131.4 Mil mean?
Karyopharm Therapeutics (KPTI) has a Total Assets of $131.4 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Karyopharm Therapeutics and its competitors.
Is Karyopharm Therapeutics' Total Assets too high?
Karyopharm Therapeutics' current Total Assets is $131.4 Mil. Overall, Karyopharm Therapeutics has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Karyopharm Therapeutics' Total Assets compare to CHRS and TARA?
Karyopharm Therapeutics' Total Assets of $131.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Karyopharm Therapeutics and its competitors. Karyopharm Therapeutics's current Total Assets is $131.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Karyopharm Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Karyopharm Therapeutics (KPTI) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.34, compared to a current price of $9.60 — trading 51.4% above its estimated fair value. The current Total Assets is $131.4 Mil. Karyopharm Therapeutics' overall GF Score™ is 52/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Karyopharm Therapeutics (KPTI), the current Total Assets is $131.4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Karyopharm Therapeutics (KPTI) Overvalued in 2026?

Based on GuruFocus' analysis, Karyopharm Therapeutics stock appears to be overvalued. The current stock price of $9.60 is trading 51.4% above its estimated GF Value™ of $6.34. GuruFocus considers Karyopharm Therapeutics to be Significantly Overvalued.

Key valuation signals for KPTI:

  • Total Assets: $131.4 Mil
  • GF Value™: $6.34 vs. price of $9.60 (51.4% above fair value)
  • GF Score™: 52/100 with 8 warning signs

No single metric tells the full story. See the KPTI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Karyopharm Therapeutics Business Description

Other Exchanges 25K0:Germany
Address 85 Wells Avenue, 2nd Floor, Newton, MA, USA, 02459
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
52GF Score

Get the complete analysis for KPTI

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.60
Price
$6.34
GF Value